Novartis aims to solve EpiPen shortage with generic launch of Symjepi to US pharmacies

pharmafile | July 10, 2019 | News story | Manufacturing and Production, Research and Development, Sales and Marketing Mylan, Novartis, Sandoz, US, epipen, pharma 

Novartis has announced the immediate availability of its generic epinephrine auto-injector in pharmacies throughout the US, as it moves to remedy the nation’s shortage of the potentially life-saving drug.

The shortage, which has now gone on for an entire year, hinges on the availability of Mylan’s EpiPen, the most common and well-known version of the drug, in what the FDA has characterised as “manufacturing delays”. The problem, according to Mylan, lies at the feet of Meridian Medical Technologies, a Pfizer subsidiary that manufactures the devices.

In response to the ongoing shortage, Novartis’ Sandoz unit made its Symjepi auto-injector available to hospitals in January, but now is extending that availability to pharmacies, as part of a commercialisation agreement with Adamis Pharmaceuticals Corp. The price for a two-pack is $250 – $50 cheaper than Mylan’s own generic version of its flagship product.  

According to Pfizer, the ongoing shortage should be expected to continue over the coming months.

Matt Fellows

Related Content

Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa

Basel, April 26, 2023 — Novartis announced today that the Committee for Medicinal Products for Human …


AstraZeneca, Klarify, and Novartis Gene Therapies top Digital Awards leaderboard

Pharmaceutical companies AstraZeneca, Klarify, and Novartis Gene Therapies all received two gold awards at the …

Expansion for first FDA-approved video game for ADHD treatment

Akili Interactive has announced the expansion of its prescription video game treatment, EndeavorRx, with the …

Latest content